JP2023542889A5 - - Google Patents

Info

Publication number
JP2023542889A5
JP2023542889A5 JP2023517700A JP2023517700A JP2023542889A5 JP 2023542889 A5 JP2023542889 A5 JP 2023542889A5 JP 2023517700 A JP2023517700 A JP 2023517700A JP 2023517700 A JP2023517700 A JP 2023517700A JP 2023542889 A5 JP2023542889 A5 JP 2023542889A5
Authority
JP
Japan
Prior art keywords
composition according
oligonucleotide
wing
bases
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542889A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/050866 external-priority patent/WO2022061108A2/en
Publication of JP2023542889A publication Critical patent/JP2023542889A/ja
Publication of JP2023542889A5 publication Critical patent/JP2023542889A5/ja
Pending legal-status Critical Current

Links

JP2023517700A 2020-09-17 2021-09-17 複数の標的を介して疼痛を処置するための治療用組成物 Pending JP2023542889A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063079912P 2020-09-17 2020-09-17
US63/079,912 2020-09-17
US202163180875P 2021-04-28 2021-04-28
US63/180,875 2021-04-28
PCT/US2021/050866 WO2022061108A2 (en) 2020-09-17 2021-09-17 Therapeutic compositions for treating pain via multiple targets

Publications (2)

Publication Number Publication Date
JP2023542889A JP2023542889A (ja) 2023-10-12
JP2023542889A5 true JP2023542889A5 (cg-RX-API-DMAC10.html) 2024-09-26

Family

ID=80775585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517700A Pending JP2023542889A (ja) 2020-09-17 2021-09-17 複数の標的を介して疼痛を処置するための治療用組成物

Country Status (6)

Country Link
US (2) US12152243B2 (cg-RX-API-DMAC10.html)
EP (1) EP4214319A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023542889A (cg-RX-API-DMAC10.html)
AU (1) AU2021345266A1 (cg-RX-API-DMAC10.html)
CA (1) CA3195722A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022061108A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542889A (ja) 2020-09-17 2023-10-12 キュー-ステート バイオサイエンシーズ, インコーポレイテッド 複数の標的を介して疼痛を処置するための治療用組成物
EP4731643A2 (en) * 2023-06-26 2026-04-29 Navega Therapeutics, Inc. Compositions and methods for reducing pain and inflammation through epigenetic modulation
WO2026080897A1 (en) 2024-10-11 2026-04-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of chronic pain

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
GB0120238D0 (en) 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
EP1478656B1 (en) 2002-02-01 2009-09-16 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US20040097440A1 (en) 2002-11-11 2004-05-20 Isis Pharmaceuticals Inc. Modulation of jumonji expression
AU2003268096A1 (en) * 2002-08-14 2004-03-03 Pharmacia Corporation ANTISENSE MODULATION OF Nav1.3 EXPRESSION
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2284269B1 (en) 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
US7341835B2 (en) 2004-01-13 2008-03-11 Affymetrix, Inc. Methods of analysis of alternative splicing in mouse
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
WO2006047687A2 (en) 2004-10-27 2006-05-04 Schering Corporation Compositions and methods for short interfering nucleic acid inhibition of nav1.8
US20070154896A1 (en) 2005-02-11 2007-07-05 International Business Machines Corporation System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
AU2006311725B2 (en) 2005-11-04 2011-11-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of NAV1.8 gene
US8178503B2 (en) 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
US7901882B2 (en) 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2009033027A2 (en) 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
FR2929292A1 (fr) 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
WO2009143277A2 (en) * 2008-05-20 2009-11-26 Intradigm Corporation Compositions comprising hscn9a sirna and methods of use thereof
CN109112126B (zh) 2010-06-23 2024-06-14 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
PT2841578T (pt) 2012-04-23 2017-08-10 Biomarin Tech Bv Resumo
EP2906255B1 (en) 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
AU2014240392A1 (en) 2013-03-14 2015-11-05 Regeneron Pharmaceuticals, Inc. Human antibodies to Nav1.7
FR3007656B1 (fr) 2013-06-28 2015-06-26 Galderma Res & Dev Modulateurs du canal sodique nav1.9 pour le traitement d'une maladie cutanee inflammatoire et methodes diagnostiques
EP3169776B1 (en) 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation
GB2547586A (en) 2014-08-20 2017-08-23 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof(In the PCT request)
CN107429250B (zh) 2015-04-03 2022-03-01 Ionis制药公司 用于调节tmprss6表达的化合物和方法
EP3183347A4 (en) 2015-10-17 2018-04-18 Lifesplice Pharma LLC Splice modulating oligonucleotides and methods of use thereof
US20170319715A1 (en) 2016-02-08 2017-11-09 Circuit Therapeutics, Inc. System and method to modulate pain and itch through cutaneous transfer of genetic information
WO2017209575A1 (en) 2016-06-03 2017-12-07 Seegene, Inc. Evaluation of specificity of oligonucleotides
EP4650364A3 (en) 2016-07-06 2026-01-21 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
EP3481857B1 (en) 2016-07-06 2026-02-11 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
WO2018098328A1 (en) * 2016-11-23 2018-05-31 Alnylam Pharmaceuticals, Inc. Modified rna agents with reduced off-target effect
US11162104B2 (en) * 2017-01-24 2021-11-02 Olipass Corporation SCN9A antisense pain killer
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN112513273A (zh) 2018-06-22 2021-03-16 豪夫迈·罗氏有限公司 用于调节scn9a表达的寡核苷酸
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
JP2023542889A (ja) 2020-09-17 2023-10-12 キュー-ステート バイオサイエンシーズ, インコーポレイテッド 複数の標的を介して疼痛を処置するための治療用組成物
WO2022232395A2 (en) 2021-04-28 2022-11-03 Q-State Biosciences, Inc. Therapeutic compositions for treating pain via multiple targets

Similar Documents

Publication Publication Date Title
JP5805088B2 (ja) 遺伝子発現を阻害する組成物およびその使用
Cohen Antisense oligodeoxynucleotides as antiviral agents
JP2016522674A5 (cg-RX-API-DMAC10.html)
JP2015518712A5 (cg-RX-API-DMAC10.html)
JP2001501614A (ja) 三つの構成成分からなるキメラアンチセンスオリゴヌクレオチド
JP2018516091A5 (cg-RX-API-DMAC10.html)
JP2015523853A5 (cg-RX-API-DMAC10.html)
JP2015518710A5 (cg-RX-API-DMAC10.html)
JP2016521556A5 (cg-RX-API-DMAC10.html)
JP2015519057A5 (cg-RX-API-DMAC10.html)
TW201210611A (en) Treatment of Nicotinamide Phosphoribosyltransferase (NAMPT) related diseases by inhibition of natural antisense transcript to NAMPT
JP2015518713A5 (cg-RX-API-DMAC10.html)
WO1996032474A1 (en) Cooperative oligonucleotides
TW201200138A (en) Treatment of Atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
CA2453301A1 (en) Synthetic double-stranded oligonucleotides for specific inhibition of gene expression
JP2023500661A5 (cg-RX-API-DMAC10.html)
CN105121452A (zh) 三环核苷和由其制备的寡聚化合物
TW201219569A (en) Treatment of Sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
AU2019234917B2 (en) Inhibitors of micro-RNA 22
Lennox et al. Characterization of modified antisense oligonucleotides in Xenopus laevis embryos
JP2024506709A5 (cg-RX-API-DMAC10.html)
JP2024073525A5 (cg-RX-API-DMAC10.html)
US12152243B2 (en) Therapeutic compositions for treating pain via multiple targets
JP6882735B2 (ja) 構造強化されたmiRNA阻害剤S−TuD
CN116670276A (zh) 用于通过多个靶标治疗疼痛的治疗组合物